Complement in Pancreatic Disease—Perpetrator or Savior?

Lucas Bettac¹, Stephanie Denk², Thomas Seufferlein¹ and Markus Huber-Lang²*

¹Department of Internal Medicine I, University Hospital of Ulm, Ulm, Germany, ²Department of Orthopedic Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital of Ulm, Ulm, Germany

The complement system is a major pillar of the humoral innate immune system. As a first line of defense against pathogens, it mediates early inflammatory response and links different branches of humoral and cellular immunity. Disorders affecting the exocrine pancreas, such as acute pancreatitis, potentially lead to a life-threatening systemic inflammatory response with aberrant activation of complement and coagulation cascades. Pancreatic proteases can activate key effectors of the complement system, which in turn drive local and systemic inflammation. Beyond that, the extent of pancreas–complement interaction covers complex pro- and anti-inflammatory mechanisms, which to this day remain to be fully elucidated. This review provides a comprehensive overview of the pathophysiological role of complement in diseases of the exocrine pancreas, based on existing experimental and clinical data. Participation of complement in acute and chronic pancreatitis is addressed, as well as its role in tumor immunology. Therapeutic strategies targeting complement in these diseases have long been proposed but have not yet arrived in the clinical setting.

Keywords: pancreas, complement, pancreatitis, acinar cells, multiple organ failure, pancreatic ductal adenocarcinomas

INTRODUCTION

The pancreas is a central and highly interconnected organ, anatomically as well as metabolically. In local and systemic inflammation, the pancreas is critically involved both as target and effector. Moreover, the pancreas seems to have a so far underappreciated major impact in triggering, development, and progression of multiple organ dysfunction syndrome (MODS) (1). Clinically and experimentally, manifold interactions of the pancreas with the innate and adaptive immune system have been described (2). On a cellular level, leukocytes seem to be significantly affected by pancreatic proteases and mediators that in turn promote local pancreatic (3–5) and systemic inflammation (2). In critically ill patients, e.g., after tissue trauma–hemorrhage, during systemic inflammation, infection, or sepsis, both danger- and pathogen-associated molecular patterns can induce an excessive activation of the complement system (6). The generated complement activation products are potent drivers of local and systemic inflammation and major contributors to MODS (7, 8). However, the pathophysiological interactions of the complement cascade with the pancreas [e.g., during acute pancreatitis (AP)] are rather complex, are partially controversial, and might have been underestimated so far (9). It is even more surprising that the physiological role of complement concerning the exocrine function of the pancreas has barely been investigated.

The aim of this comprehensive review is to provide an up-to-date insight into the interactions of complement with the exocrine pancreas based on experimental and clinical data. The review will neither cover the various functions of complement in regard to the endocrine pancreas (10–14) nor...
address the potential harmful role of complement in the context of pancreas whole organ and islet transplantation (15–17). The focus of the present review is rather set on various important pancreatic diseases in the light of complement action and regulation.

**COMPLEMENT AS A MAIN PILLAR OF INNATE IMMUNITY**

The cellular and humoral defense systems of innate immunity are crucially involved in inducing and mounting local inflammatory processes, systemic inflammation, and remote organ injury. Main pathophysiological drivers of the inflammatory response are the complement and coagulation cascades, which are highly interactive and can also be considered parts of a global serine protease system (18). It is well established that severe pancreatic tissue damage and pancreatitis is associated with activation of the coagulation system, often resulting in development of coagulopathy. In contrast, activation of the complement system and development of complementopathy in the setting of severe pancreatic diseases has not been conclusively investigated so far.

The complement system as a key immune surveillance system (19) consists of more than 30 complement components, which can be activated by different pathways. Complement activation via classical, alternative, and lectin pathways has been described in great detail before. The main drivers of these pathways are outlined in Figure 1.

It is noteworthy that various complement factors can be activated in a non-canonical manner by an “extrinsic protease pathway” (19), consisting of serine proteases of the coagulation and fibrinolytic system (e.g., thrombin, plasmin, and factor VII-activating serine protease) (20, 21). Furthermore, other proteases such as granzyme B (22) and trypsin (23) are capable of cleaving and activating central complement components, leading to generation of the anaphylatoxins C3a and C5a, which in turn can induce all classical signs of inflammation.

To prevent excessive activation, hyper-inflammation, and self-attack, the complement cascade is tightly regulated and controlled by complement regulatory proteins (CRegs). Main inhibitors within the fluid phase system are the C1 inhibitor (C1INH), C4-binding protein (C4bp), complement factor H, and complement factor I. On cellular surfaces there are also some potent surface-bound CRegs, e.g., complement receptor 1 (CR1, CD35), membrane cofactor protein (MCP, CD46), decay accelerating factor (DAF, CD55), and membrane inhibitor of reactive lysis (CD59). The balance between complement activation products and counteracting CRegs may be disturbed in many diseases, especially by the uncontrolled release of other potent proteases, e.g., during massive activation of the coagulation system or during inflammatory processes of the pancreas.

**EXOCRINE PANCREAS AND COMPLEMENT AS CENTRAL PLAYERS IN MULTIPLE ORGAN DYSFUNCTION**

It has been suggested that digestive enzymes (prematurely) released from the exocrine pancreas can enter the circulation via dysfunctional organ barriers. In the systemic circulation, these pancreas-derived proteases may cleave off cellular surface molecules and receptors and activate other proteases (24, 25), such as coagulation, fibrinolytic, and complement factors. The resulting “autodigestion” and dysregulation of important innate immune cascades reflect main pathophysiological features of MODS. Activated trypsin has been suggested to be ultimately responsible for MODS development, causing enhanced global organ permeability, blood exudate leakage, and coagulation dysfunction (26).

Other mechanisms by which local pancreatic damage affects MODS have also been proposed. In experimental pancreatitis, reduction of phosphorylation processes, impairment of the respiratory chain, and resulting severe mitochondrial dysfunction were found to facilitate further pancreatic damage. Beyond these local effects, mitochondrial function in the lungs and kidneys was also reduced early after induction of pancreatitis (27). A time-dependent onset of MODS (lung, kidney, heart, and liver) induced by experimental pancreatitis with associated acinar cell necrosis and systemic inflammatory response has been reported to involve neutrophil influx and extracellular regulated kinase (ERK) activation (28). Immune cell infiltration of lung tissue during experimental pancreatitis has been shown to be accompanied by enhanced expression of endothelial adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) (29). Furthermore, when AP is complicated by infection, the excessive cytokine release and inflammatory response by macrophages further prime neutrophils for a “second attack” on remote organs (30).
FIGURE 1 | Continued
The classical pathway recognizes immunoglobulins (IgM/IgG) and pentraxins (such as C-reactive protein) and forms and activates a C1 complex, leading to the cleavage of C4 and C2. The cleavage products C4b and C2a form the C3 convertase C4b2a of the classical pathway, which in turn cleaves the central complement component C3 into the anaphylatoxin C3a and opsonin C3b. The C3 convertase can also be formed and activated by the lectin pathway, in which mannose-binding lectin (MBL) and ficolins recognize pathogenic patterns, leading to the activation of MBL-associated serine proteases MASP-1 and MASP-2. The alternative pathway, triggered by various danger- and pathogen-associated molecular patterns (DAMPs and PAMPs, respectively) on necrotic, apoptotic, and foreign surfaces, involves hydrolysis of C3 and cleavage by other complement factors. Binding of factor B (FB) to C3(H2O) results in the formation of an alternative fluid phase C3 convertase. C3 is cleaved, and C3b binds FB to form the surface-bound main C3 convertase of the alternative pathway, which is stabilized by properdin (P) and can in turn induce all functions of complement (C3bBbP). The alternative pathway also constitutes an amplification loop for the complement cascade, with C3b as a feedback effector. Besides enhancing the complement response, as an opsonin, C3b is also essential for the clearance of pathogens and tissue debris. Downstream of the converging activation pathways, the C3 convertases of both classical and alternative pathways bind C3b and form the respective C5 convertases. Those cleave C5, producing the potent anaphylatoxin C5a and C5b. The latter, together with several other complement factors (C6, C7, C8, and C9), forms the terminal complement complex (TCC), also known as membrane attack complex. This C5b–9 complex induces both pro- and anti-inflammatory cell signaling pathways and is also capable of forming a lytic pore. Cleavage and activation of central complement components is also possible by proteases typically not associated with the complement system, such as trypsin—effectively constituting a fourth, non-canonical extrinsic protease pathway of complement activation (targets shown exemplarily). Important regulators of the complement cascade (CRegs) are C1 inhibitor (C1INH), factor H (FH), and membrane inhibitor of reactive lysis (CD59). Several CRegs control the formation, activity, and degradation of C3 convertase, which can be classical, alternative, or both. CD35, C4bp, and FH, shown here acting on the convertases themselves, can also function as cofactors for FI-mediated cleavage of upstream components C3b or C4b. CD35 = complement receptor 1 (CR1); CD46 = membrane cofactor protein (MCP); CD55 = decay accelerating factor (DAF); FI, factor I; C4bp, C4-binding protein.

Complement activation seems to happen by both classical and alternative complement pathways, and the extent of changes in complement serum levels shows a correlation with the clinical severity of disease (36, 46, 47).

Only severe necrotizing pancreatitis, but not mild edematous AP, in rats was accompanied by detectable complement deposits in a murine model of dl-ethionine-induced AP (43, 44).

On the other hand, cleavage of C3 by the pancreatic protease trypsin with subsequent complement activation, a process only partly ameliorated by anti-proteolytic mechanisms in the process of excess trypsin release and activation, provides evidence of strong pancreas–complement interaction (45) (Figure 3). Complement activation seems to happen by both classical and alternative complement pathways, and the extent of changes in complement serum levels shows a correlation with the clinical severity of disease (36, 46, 47).
by early complement activation with increased levels of C3a (48). Similar results linking decreasing complement hemolytic activity (CH50), acinar C3 deposits, and histological tissue damage could be found in a rodent model of AP (49). It is noteworthy that complement consumption in early AP can be accompanied by persistently lowered serum complement levels several weeks after the onset of symptoms (50).

In the clinical setting, C3a and sC5b–9 are elevated in the serum of patients with early AP and also show an excellent correlation with severity of disease, suggesting them as potential biomarkers for severe AP with high specificity and sensitivity (51). Patients who developed pancreatic pseudocysts as a result of AP showed changes in plasma complement activity and protease inhibitors similar to those seen in moderate to severe AP without pseudocysts (52). Pseudocyst fluid itself, as well as ascites of patients with AP, has been shown to contain high levels of C5a and terminal complement complex (TCC) (47).

Vice versa, in the absence of C5, C5-deficient mice develop significantly less pancreatic edema in the course of AP (53).

One recent study quantifying mannose-binding lectin (MBL) pathway effectors in AP patient sera found no significant correlation between levels of MBL, MBL-associated serine protease 2, and severity or mortality of disease. These findings suggest that the MBL pathway of complement activation only plays a minor role in AP pathogenesis (54). Fittingly, pancreatic MBL, isolated from pancreatic juice and identified as pancreatic elastase III, could not be shown to induce complement-mediated lysis, contrasting starkly with other known MBL isoforms (55).

The role of protease–anti-protease imbalance in this context has been extensively discussed, with contrasting results by different researchers, hinting at a more prominent role in local
intraperitoneal trypsin activity as opposed to systemic (serum) activity. A low level of the anti-protease alpha-2-macroglobulin is an universally acknowledged predisposing factor for high trypsin activity (46, 56–59). Regarding protease–complement interactions, trypsin-induced C3 cleavage could be inhibited in vitro by high levels of pancreatic secretory trypsin inhibitor (60).

In addition to excessive complement cleavage and activation, loosening of physiologic inhibitory mechanisms controlling complement activity also plays a role in the pathophysiology of AP. The complement activation regulators CD46, CD55, and CD59, normally expressed on pancreatic acinar cells, are downregulated in sodium taurocholate-induced severe AP, and decreased expression is correlated with more severe necrosis. Downregulation of CD55 and CD59 could be alleviated by IL-4, with a positive effect on disease severity (61).

Interactions between humoral innate immunity and cellular immunity are decisive in the inflammatory response associated with AP. Different immune cells have been identified as important effectors in AP, especially macrophages and neutrophils (62). While data are scarce on macrophage/monocyte involvement in pancreatic complement modulation, the activation of neutrophil granulocytes by the complement system has been a focus of research. Especially, C5a is known to be a strong chemotactant for neutrophil recruitment to damaged and inflamed tissue and can induce phagocytosis, release of cytokines, and oxidative burst with release of reactive oxygen species (63). Thus, C5a may represent a main driver for neutrophil migration to pancreatic tissue, as well as to lung tissue in AP-related ARDS (64) (Figure 4). Neutrophils incubated with serum from rats suffering from necrotizing AP showed increased expression...
of the adhesion molecule membrane attack complex (MAC)-1 (CD11b/18, complement receptor 3). In addition, injection of AP serum into lung tissue led to local neutrophil sequestration. Both effects were averted by complement inhibition with soluble complement receptor type 1 (sCR1) (65). In another rat model of acute severe/necrotizing and mild/edematous AP, inhibition of complement activation by administration of sCR1 decreased leukocyte–complement interaction and local and remote lung damage (48). Severe necrotizing AP seems to lead to a reduced expression of opsonin receptors, including complement receptor 3 on local peritoneal neutrophils, and enhanced expression on circulatory neutrophils. Nearly opposite changes were found in mild pancreatitis (66, 67). A 2001 study by Kyriakides et al. assessed the effects of total neutrophil and/or complement depletion in experimental AP. While local pancreas damage was not modified by either of these, neutropenia, but not complement depletion, showed a beneficial effect on remote organ injury and overall survival (68). This suggests that besides complement-mediated neutrophil activation, other mediators significantly contribute to the activation of cellular immune response during AP.

Contrasting anti-inflammatory effects of complement components have been reported in a 2001 study conducted by Bhatia et al. (69). In genetically modified mice lacking either C5 or C5a receptor, cerulein-induced pancreatitis was characterized by a distinctly more severe clinical progression as compared to wild-type mice, with aggravated local pancreas as well as remote lung injury. These findings hint at an anti-inflammatory role of C5a in AP. It should be noted that, when excessively generated, C5a eventually results in a functional paralysis of the neutrophil response (70) and thereby might represent a mechanism for inhibiting neutrophil-mediated pancreatic damage.

In conclusion, the role of the complement system in AP seems to be highly complex and is not yet fully understood. Opposing interactions concerning local and systemic inflammatory response have been proposed. Likely, both pro- and anti-inflammatory effects are conveyed by different key components within the complement cascade. On another note, the widespread usage of a number of different animal models, which vary considerably in their modes and mechanisms of AP induction, may have contributed to conflicting results.

### IMPLICATION OF COMPLEMENT IN CHRONIC PANCREATITIS (CP) AND AUTOIMMUNE PANCREATITIS (AIP)

In comparison to AP, not much research has been done on the role of complement in chronic or recurring pancreatitis as well as in AIP. The latter is sometimes associated with decreased serum complement levels, accompanied by high levels of circulating immune complexes during the active phase of disease, an effect hinting at complement activation via the classic pathway (71, 72). These immune complexes lead to the destruction of acinar cells and small- to medium-sized pancreatic ducts, as suggested by fluorescence staining for basal membrane deposits of C3c and immunoglobulins (73).

Concerning complement activity in CP, a recent study by Sendler et al. showcases the involvement of complement C5 in the development of fibrosis during CP. In C5-deficient mice, CP was induced by pancreatic duct ligation and cerulein injection or recurring cerulein injections alone. Mice lacking C5, as well as wild-type mice subjected to treatment with C5a-receptor antagonists, showed significantly reduced pancreatic fibrosis in later stages of disease. This seems to be a consequence of recruitment and activation of pancreatic stellate cells by C5a, shown in vitro and in vivo, leading to the production of extracellular matrix proteins (e.g., collagen type I, fibronectin, and αSMA) and fibrosis (74). Interestingly, no major differences in disease severity and organ damage were noted during early stages of pancreatitis, which contradict the common understanding of complement involvement in AP.

### POTENTIAL ROLE OF COMPLEMENT IN PANCREATIC TUMORIGENESIS

Pancreatic cancer is among the most lethal common malignancies, as it is usually diagnosed at an advanced stage when curative therapies are no longer available. Pancreatic ductal adenocarcinomas (PDAC) constitute the overwhelming majority of pancreatic neoplasms. PDAC is characterized by extensive stromal desmoplasia, which promotes a hypovascular tumor microenvironment and immune evasion.

The inhibitory complement regulatory proteins CD46, CD55, and CD59 are known to be overexpressed in PDAC cell lines in a manner similar to other tumor entities (75, 76). This may contribute to immune evasion and impedes the potential of new immunotherapeutic strategies with monoclonal antibodies, which typically rely on complement-mediated cytotoxicity (77). Elevated serum levels of the inhibitory anti-proteases alpha-2-macroglobulin and C1INH constitute an additional mechanism of complement resistance in pancreatic cancer (78). Proteomic analysis of the cell line secretome confirmed inhibition of the complement system as a major functional alteration in PDAC (79). Furthermore, it has been shown that under inflammatory conditions, complement C3 secretion in PDAC cell lines was inhibited by TGF-β, a cytokine strongly involved in PDAC progression and tissue desmoplasia (80, 81).

Inhibition of the MBL pathway of complement activation has been described for a subgroup of PDAC patients. In a phase II clinical trial, treatment with ω-3-rich fatty acids in addition to chemotherapy restored MBL activity and improved patient survival (82).

The search for novel potential biomarkers for pancreatic cancer has led to several studies involving proteomics analysis of PDAC patient sera. Several authors describe elevated serum levels of complement components, such as C3, C3c, C5a, and C5b–9/MAC (83–86), as well as soluble iC3b, a complement product generated by the interaction with the abundantly expressed CRregs (87). Complement factor B has been proposed as a promising new serological biomarker for PDAC, supplementing CA 19-9 (88). However, biomarker performance, including C5, is severely impeded by obstructive jaundice, a pathology common in pancreatic cancer (89).
It is also notable that C4b1 expression in tumor tissue correlates with TNM staging (TNM Classification of Malignant Tumours, in which extent of disease is assessed by tumor size and infiltration, lymph node, and distant metastasis), with locally advanced and metastatic tumors showing higher expression levels (90).

To give one example for the relevance of complement in the setting of non-adenocarcinoma tumors of the pancreas, one recent study found a pro-tumorigenic role for C5 in neuroendocrine pancreatic tumors, with C5-deficient mice showing smaller primary tumors and fewer metastases. Likewise, in human NET samples, advanced tumors showed higher C5 expression than tumors with lower TNM staging (91).

Taken together, these findings suggest a balance of pro-inflammatory and anti-inflammatory complement modulation in PDAC. Pancreatic cancer is known to induce a pro-inflammatory microenvironment, promoting growth and metastasis, which involves the classical complement pathway. On the other hand, immune evasion of cancer cells themselves could be mediated by inhibition of MBL and upregulation of membrane-bound complement regulators.

**THERAPEUTIC COMPLEMENT STRATEGIES IN PANCREATIC DISEASES**

Considering the aforementioned widespread implications of complement in the pathophysiology of a variety of different pathologies of the pancreas, only limited data exist on the possible therapeutic possibilities of targeted complement modulation in these diseases.

Combined treatment with C1 esterase inhibitor, an inhibitor of the classical complement pathway, and antithrombin III improved survival in a rodent model of severe AP. In contrast, the same treatment showed no significant benefit in mild edematous AP (92). Likewise, treatment with C1 esterase inhibitor improved the clinical outcome of severe AP after allogeneic hematopoietic stem cell transplantation in a case study of two pediatric patients. This therapeutic effect was mainly attributed to reduction of capillary leakage and subsequent cardiovascular stabilization (93). In a small-scale study of patients undergoing endoscopic papillosphincterotomy, C1INH prevented hyperamylasemia, a possible precursor of post-ERCP pancreatitis (94).

One other study found no beneficial effect of complement inhibition by sCRI on cerulein-induced AP (95), while a later study with comparable methodology found an ameliorating effect on neutrophil accumulation in lung tissue, indicating therapeutic options for distant organ damage (96).

The positive effect of C5a-receptor blockade by the small molecule inhibitor W-54011 on fibrosis and disease progression in a rodent model of CP suggests therapeutic applicability in the chronic setting (74). One earlier study had seen similar results for the serine protease inhibitor camostat (97). Owning to the more generalized nature of inhibition, broad band serine protease inhibitors, although effective in complement inhibition, could be expected to carry more unwanted side effects than targeted complement inhibition. A recent meta-analysis of 17 clinical trials conducted over the last five decades could find no evidence for a beneficial effect of i.v. treatment with protease inhibitors on overall mortality in AP (98). Overall, no therapeutic strategies targeting complement in pancreatic diseases have been clinically established so far although complement modulation seems promising for the treatment of acute and CP.

**FUTURE AVENUES FOR COMPLEMENT RESEARCH IN PANCREATIC DISEASES**

The data available clearly point to an important role of complement in induction and progression of acute and chronic inflammatory pancreatic diseases. However, it needs to be clarified whether the apparent Janus-faced nature of C5a in the development of pancreatitis is merely a question of concurrence with anti-inflammatory features during acute and pro-inflammatory features during chronic inflammation.

It is noteworthy that plasma anaphylatoxin levels correlate with the severity of pancreatitis (36, 46, 47). Therefore, it would be of utmost interest to determine whether this is only a reflection of systemic inflammation, or if the complement activation products are causative to induction and progression of pancreatitis and resulting complications. It seems that the role of local, uncanonical activation of complement by prematurely activated pancreatic proteases in the progression of pancreatitis has been rather underestimated. Thus, it is of importance to define which complement components can be locally produced by acinar cells and ductal epithelium and investigate the conditions of local complement cleavage and activation. In this regard, it is also surprising that no reports exist on the different anaphylatoxin receptor status (e.g., C3aR, C5aR1, and C5aR2) of pancreatic acinar cells. If detected, it would be of interest to characterize cellular signaling and functional consequences of these receptors.

Investigations of the role of complement in chronic inflammatory microenvironmental changes and cancer development are, if at all, in statu nascendi, but the subject certainly offers ample room for promising future research. In the light of recent findings linking C5 to fibrosis in CP (74), complement involvement in PDAC desmoplastic stromal response could prove to be an interesting research topic. Furthermore, it has been shown in non-pancreatic tissues that complement proteins contribute to immune surveillance of malignant tumors (99). C5a in the tumor microenvironment notably enhanced tumor growth by inhibiting CD8+ T cell-mediated antitumor effects (100). On the other hand, ic3b opsonizes tumor surfaces and thereby supports tumor cell cytotoxicity, which is aided by a functional TCC (101). These contrasting findings highlight the need for further research into the role of complement components in pancreatic tumor development.

**AUTHOR CONTRIBUTIONS**

LB contributed to the conception, drafting, and writing of the manuscript, design and preparation of the figures, final approval, and agreement to any part of the work. SD contributed to the conception of the manuscript, critical revision of the work, design and preparation of the figures, final approval, and agreement to any part of the work. TS contributed to the conception of the
References

1. Gasparovic V, Dakovic K, Gornik I, Radonic R. Severe acute pancreatitis as a part of multiple dysfunction syndrome. Coll Antropol (2014) 38:125–8.

2. Shamoon M, Deng Y, Chen YQ, Bhatia M, Sun J. Therapeutic interventions of innate immune system in acute pancreatitis. Expert Opin Ther Targets (2016) 20:73–87. doi:10.1517/14728222.2015.1077227

3. Chen G, Xu F, Li J, Lu S. Depletion of neutrophils protects against l-arginine-induced acute pancreatitis in mice. Cell Physiol Biochem (2015) 35:2111–20. doi:10.1159/000374017

4. Merza M, Hartman H, Rahman M, Hwaiz R, Zhang E, Renstrom E et al. Neutrophil extracellular traps induce trypsin activation, inflammation, and tissue damage in mice with severe acute pancreatitis. Gastroenterology (2015) 149:1920–31. doi:10.1053/j.gastro.2015.08.026

5. Schmidt AI, Seifert GJ, Lauch R, Wolff-Verbeck G, Chikhladze S, Hopt UT et al. Organ-specific monocyte activation in necrotizing pancreatitis in mice. J Surg Res (2015) 197:374–81. doi:10.1016/j.jsre.2015.03.075

6. Ehrnhaller C, Ignatius A, Gebbard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med (2011) 17:317–29. doi:10.2119/molmed.2010.00149

7. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF et al. Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 166:1193–9. doi:10.4049/jimmunol.166.2.1193

8. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multiorgan failure. Clin Dev Immunol (2012) 2012:962927. doi:10.1155/2012/962927

9. Mansfield C. Pathophysiology of acute pancreatitis: potential application from experimental models and human medicine to dogs. J Vet Intern Med (2012) 26:875–87. doi:10.1111/j.1939-1676.2012.00949.x

10. Luan NM, Iwata H. Xenotransplantation of islets enclosed in agarose microcapsule carrying soluble complement receptor 1. Biomaterials (2012) 33:8075–81. doi:10.1016/j.biomaterials.2012.07.048

11. Phiel G, Garcia-Martin R, Lambris JD, Korsgren O, Nilsson B. Acute anti-donor antibodies related to worse outcome for patients. Ann Transplant (2011) 14:29–35.

12. Tjernberg J, Ekdahl KN, Lambris JD, Korsgren O, Nilsson B. Acute anti-donor antibodies related to worse outcome for patients. Nat Immunol (2010) 11:785–97. doi:10.1038/ni.2033

13. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al. Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 185:5628–36. doi:10.4049/jimmunol.0903678

14. Tokodai K, Goto M, Inagaki A, Imura T, Nakanishi W, Satomi S. Expression of receptors for anaphylatoxins C3a and C5a on rat islet preparations. Transplant Proc (2011) 43:3179–80. doi:10.1016/j.transproceed.2011.10.006

15. de Kort H, Munivenkatappa RB, Berger SP, Eikmans M, van der Wal A, de Koning EJ et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant (2010) 10:1660–7. doi:10.1111/j.1600-6143.2010.03079.x

16. Munivenkatappa RB, Philosoph B, Papadimitriou JC, Drachenberg CB. Interacinar c4d staining in pancreas allografts. Transplantation (2009) 88:145–6. doi:10.1097/TP.0b013e3181ace779

17. Suermann A, Vonend O, Schenker P, Viebahn R, Rump LC, Weiner SM. Plasma complement 3d levels in the early phase after pancreas transplantation. Ann Transplant (2009) 14:29–35.

18. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 12:682–7. doi:10.1038/nm1419

Funding

This study was supported by grants from the German Research Foundation DFG assigned to the Collaborative Research Centre 1149 “Trauma” (A01, Z02).
activation and the onset of acute pancreatitis. *J Clin Invest* (2000) 106:773–81. doi:10.1172/JCI9411

39. Seelig R, Ehrenaut T, Tchalhargane C, Seelig HP. The serum complement system – a mediator of acute pancreatitis. *Virchows Arch A Pathol Anat Histol* (1975) 365:193–9. doi:10.1007/BF00434038

40. Seelig R, Seelig HP. Complement-mediated acinar cell necrosis in pancreatitis induced by basement membrane antibodies. *Virchows Arch A Pathol Anat Histol* (1976) 371:69–77. doi:10.1007/BF00433716

41. Seelig R, Seelig HP, Rohnaeher R. Acute pancreatitis induced by intrapancreatic complement activation in the rat. *Z Gastroenterol* (1976) 14:654–7.

42. Goldstein IM, Cala D, Radin A, Kaplan HB, Horn J, Ranson J. Evidence of complement catabolism in acute pancreatitis. *Am J Med Sci* (1978) 275:257–64. doi:10.1097/0000441-197805000-00033

43. Kelly RH, Rao KN, Harvey VS, Lombardi B. Acute hemorrhagic pancreatitic necrosis in mice: lack of a pathogenic role for complement. *Acta Hepatogastroenterol (Stutt)* (1979) 26:302–9.

44. Kelly RH, Rao KN, Harvey VS, Lombardi B. Acute hemorrhagic pancreatic necrosis in mice: alterations of serum complement. *Digestion* (1981) 22:1–7. doi:10.1159/000198588

45. Roxvall L, Bengtson A, Sannerby L, Heideman M. Activation of the complement cascade by trypsin. *Biochim Biophys Acta* (1976) 391:273–8. doi:10.1016/0162-5881(76)90236-X

46. Asson KL, Laubell AB, Ohlsson K. Correlation among complement activation, prokaryotic inhibitors and clinical course in acute pancreatitis. *Scand J Gastroenterol* (1985) 20:335–45. doi:10.3109/03655528509196161

47. Roxvall LI, Bengtson LA, Heideman JM. Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and ascites fluid of patients with acute pancreatitis. *Arch Surg* (1990) 125:918–21. doi:10.1001/archsurg.1990.01410190116019

48. Hartwig W, Klaas M, Kirschfink M, Hackert T, Schneider L, Gebhard MM, et al. Interaction of complement and leukocytes in severe acute pancreatitis: potential for therapeutic intervention. *Am J Gastroenterol* (1996) 91:2844–50. doi:10.1111/j.1572-0241.1996.tb12449.x

49. Seelig R, Lankisch PG, Koop H, Windker K, Kaboth U, Seelig HP. Complement system in sodium taurocholate pancreatitis in the rat. *Res Exp Med (Berl)* (1978) 174:57–65. doi:10.1007/BF01851939

50. Antal I, Kavai M, Varhelyi I, Szegedi G. Abnormalities in humoral and cellular immune activity in pancreatitis. I. Study of the humoral immune system. *Acta Med Acad Sci Hung* (1978) 35:69–79.

51. Gloor B, Stahel P, Muller CA, Schmidt OI, Buchler MW, Uhl W. Predictive value of complement activation fragments C3a and C5b-9 for development of severe disease in patients with acute pancreatitis. *Scand J Gastroenterol* (2003) 38:1078—82. doi:10.1080/00365520310005985

52. Asson KL, Ohlsson K. Pancreatic pseudocysts: a biochemical evaluation of complement C3c, immunoglobulin (Ig)G4 and IgG at the basement membrane of severe disease in patients with acute pancreatitis. *Scand J Gastroenterol* (2006) 40:1097–102. doi:10.1080/00365520600981866

53. Merriam LT, Webster C, Joehl RJ. Complement component C5 deficiency reduces edema formation in murine ligation-induced acute pancreatitis. *J Surg Res* (1997) 67:40–5. doi:10.1006/jsre.1996.1991

54. Novovic S, Andersen AM, Erbsoll AK, Jorgensen LN, Nielsen HJ, Jensenius JC, et al. Mannan-binding lectin and mannann-binding lectin-associated serine protease 2 in acute pancreatitis. *Pancreas* (2011) 40:1097–102. doi:10.1097/MPA.0b013e31821b5a72

55. Zhang H, Patel SA, Kandlikar E, Mueller CM, Lin YY, Zenilman ME. Pancreatic elastase is proven to be a mannose-binding protein – implications for the systemic response to pancreatitis. *Surgery* (2003) 133:678–88. doi:10.1067/msy.2003.175

56. Balldin G, Eddelang A, Ohlsson K. Studies on the role of the plasma protease inhibitors in vitro C3 activation and in acute pancreatitis. *Scand J Gastroenterol* (1981) 16:603–9. doi:10.3109/036555231091982018

57. Horn JK, Ranson JH, Goldstein IM, Weisler J, Curatola D, Taylor R, et al. Evidence of complement catabolism in experimental acute pancreatitis. *Am J Pathol* (1980) 101:205–16.

58. Asson KL, Ohlsson K. On the potential role of trypsin and trypsin inhibitors in acute pancreatitis. *Adv Exp Med Biol* (1984) 167:477–87. doi:10.1007/90978-1-4651-9353-3_42

59. Schmid S, Uhl W, Buchler MW. Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. *Scand J Gastroenterol* (2003) 36:219–50. doi:10.1080/0365552960917786

60. Ohlsson K. Influence of the human pancreatic secretory trypsin inhibitor on trypsin-induced C3 and kinnogen cleavage: an in vitro study. *Scand J Gastroenterol* (1987) 22:164–20. doi:10.3109/00365528609091886

61. Zhang C, Ge CL, Guo RX, He SG. Effect of IL-4 on altered expression of complement activation regulators in rat pancreatic cells during severe acute pancreatitis. *World J Gastroenterol* (2005) 11:6770–4. doi:10.3748/wjg.v11.43.6770

62. Shrivastava P, Bhattachar P. Essential role of monocytes and macrophages in the progression of acute pancreatitis. *World J Gastroenterol* (2010) 16:3995–4002. doi:10.3748/wjg.v16.33.3995

63. Lasson A, Ohlsson K. Pancreatic pseudocysts: a biochemical evaluation of systemic response to pancreatitis. *Am J Physiol* (2000) 278:G273–66. doi:10.1152/ajpgi.2000.278.3.G273

64. Solomkin JS, Cotta LA, Satoh PS, Hurst JM, Nelson RD. Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man. *Surgery* (1985) 97:678–87.

65. Hartwig W, Limene RE, Fernandez-del CC, Kellihier A, Jones R, Warshaw AL. Expression of the adhesion molecules Mac-1 and L-selectin on neutrophils in acute pancreatitis is protease- and complement-dependent. *Ann Surg* (2001) 233:371–8. doi:10.1096/annahs.20011020000111

66. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, et al. Complement-induced impairment of innate immunity during sepsis. *J Immunol* (2002) 169:3223–31. doi:10.4049/jimmunol.169.6.3223

67. Uchida K, Fukui T, Takaoka M, Nishio A. Autoimmune pancreatitis and complement activation system. *J Gastroenterol Hepatol* (2006) 21:603–9. doi:10.1111/j.1440-1746.2006.04055.x

68. okazaki K, Taniyama K, Mino K. Autoimmune pancreatitis – a new evolving pancreatic disease? *Langenbecks Arch Surg* (2010) 395:899–900. doi:10.1007/s00423-010-0714-2

69. Schmid S, Uhl W, Buchler MW. Protease-antiprotease interactions and the rationale for therapeutic protease inhibitors. *Scand J Gastroenterol* (2003) 36:219–50. doi:10.1080/0365552960917786
Bettac et al.

90. Chen J, Wu W, Zhen C, Zhou H, Yang R, Chen L, et al. Expression and clinical significance of complement C3 biosynthesis in human pancreatic cancer cell lines. *Panceras* (2000) 20:138–45. doi:10.1097/00006676-20000300-00005

91. Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, et al. Transforming growth factor-beta1 acts as a potent inhibitor of complement C3 biosynthesis in human pancreatic cancer cell lines. *Panceras* (2010) 9:4376–92. doi:10.1021/pr1001109

92. Andoh A, Shimada M, Takaya H, Hata K, Fujiyama Y, Bamba T. Transforming growth factor-beta1 inhibition in pancreatic and hepatocellular carcinomas. *Oncotarget* (2014) 5:78–94. doi:10.18632/oncotarget.1569

93. Chen J, Wu W, Chen L, Zhou H, Yang R, Chen L, et al. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of complement C3 and alpha-2-HS-glycoprotein. *Pancerasology* (2013) 13:290–7. doi:10.1016/j.pan.2013.03.010

94. Hansa JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, et al. Biomarker identification in functional human pancreas cancer sera. *Panceras* (2008) 36:61–9. doi:10.1097/MPA.0b013e31800e0ca738

95. Padoan A, Seraglia R, Basso D, Fogar P, Sperti C, Moz S, et al. Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer. *Panceras* (2013) 42:622–32. doi:10.1097/MPA.0b013e318273096c

96. Starzynska T, Dabkowski K, Błogowski W, Zuba-Surma E, Budowska M, Salata D, et al. An intensified systemic trafficking of bone marrow-derived stem/progenitor cells in patients with pancreatic cancer. *J Cell Mol Med* (2013) 17:792–9. doi:10.1111/jcmm.12065

97. Marten A, Buchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. *J Immunother* (2010) 33:219–24. doi:10.1097/JIT.0b013e3181bed29f

98. Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, et al. Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in obstructive jaundice on their performance. *Oncol Lett* (2013) 6:438–8. doi:10.3892/ol.2013.1326

99. Schneider DT, Nurnberger W, Stannigel H, Bonig H, Gobel U. Combined treatment with CI esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. *Gut* (1997) 40:531–5. doi:10.1136/gut.40.4.531

100. Schneider DT, Nurnberger W, Stannigel H, Bonig H, Gobel U. Adjuvant treatment of severe acute pancreatitis with CI esterase inhibitor concentrate after haematopoietic stem cell transplantation. *Gut* (1999) 45:733–6. doi:10.1136/gut.45.5.733

101. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? *Ann Ital Med Intern* (1994) 9:180–2.

102. Weiser MR, Gibbs SA, Moore FD Jr, Hechtman HB. Complement inhibition by soluble complement receptor type 1 fails to moderate ceruline-induced pancreatitis in the rat. *Int J Pancreatol* (1996) 19:129–34.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Bettac, Denk, Seufferlein and Huber-Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.